A new experimental drug for menopause reduced the frequency and severity of hot flashes by 83 percent [1] in a mid-stage trial.
These results provide a potential alternative for women who cannot or choose not to use hormone replacement therapy due to associated health risks. The development marks a shift toward non-hormonal interventions for managing menopausal symptoms.
AbCellera, a biotech company based in Vancouver, reported the trial findings on Monday. The experimental treatment targets the symptoms of menopause without utilizing hormones, a method that could broaden treatment options for millions of women.
"The magnitude of the effect was interesting," senior author Dr. Pauline M. Maki said.
The announcement triggered a significant market reaction for the biotech firm. AbCellera shares increased by nearly 40 percent [2] following the release of the trial data.
While the AbCellera drug remains in the experimental stage and is not yet approved for public use, other non-hormonal options are entering the market. In June, drugmaker Bayer announced that the U.S. FDA approved a separate once-a-day non-hormonal pill designed to treat hot flashes [3].
Medical researchers said that these new developments aim to reduce the reliance on traditional hormone therapy. The goal is to offer a safer profile for patients who may have contraindications for hormonal treatments, such as a history of certain cancers, or cardiovascular issues.
“A new experimental drug for menopause reduced the frequency and severity of hot flashes by 83 percent.”
The emergence of both an experimental high-efficacy drug from AbCellera and an FDA-approved pill from Bayer indicates a diversifying landscape in women's health. By decoupling menopause symptom management from hormone therapy, the medical community is creating a pathway for patients who were previously ineligible for treatment due to the risks associated with estrogen and progesterone.
